REFERENCES:
  1. Martin PJ. How I treat steroid-refractory acute graft-versus-host disease. Blood. 2020 May 7;135(19):1630-1638.
  2. McDonald GB. How I treat acute graft-versus-host disease of the gastrointestinal tract and the liver. Blood. 2016 Mar 24;127(12):1544-1550.
  3. Penack O, Marchetti M, Ruutu T, Aljurf M, Bacigalupo A, Bonifazi F, Ciceri F, Cornelissen J, Malladi R, Duarte RF, Giebel S, Greinix H, Holler E, Lawitschka A, Mielke S, Mohty M, Arat M, Nagler A, Passweg J, Schoemans H, Socié G, Solano C, Vrhovac R, Zeiser R, Kröger N, Basak GW. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol . 2020 Feb;7(2):e157-e167.
  4. Tawara I, Sun Y, Lewis EC, Toubai T, Evers R, Nieves E, Azam T, Dinarello CA, Reddy P. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A . 2012 Jan 10;109(2):564-569.
  5. Marcondes AM, Karoopongse E, Lesnikova M, Margineantu D, Welte T, Dinarello CA, Hockenbery D, Janciauskiene S, Deeg HJ. α-1-Antitrypsin (AAT)-modified donor cells suppress GVHD but enhance the GVL effect: a role for mitochondrial bioenergetics. Blood . 2014 Oct 30;124(18):2881-2891.
  6. Marcondes AM, Hockenbery D, Lesnikova M, Dinarello CA, Woolfrey A, Gernsheimer T, Loghman-Adham M, Gelmont D, Storer B, Hansen JA, Deeg HJ. Response of Steroid-Refractory Acute GVHD to α1-Antitrypsin.Biol Blood Marrow Transplant . 2016 Sep;22(9):1596-1601.
  7. Magenau JM, Goldstein SC, Peltier D, Soiffer RJ, Braun T, Pawarode A, Riwes MM, Kennel M, Antin JH, Cutler CS, Ho VT, Alyea EP 3rd, Parkin BL, Yanik GA, Choi SW, Lewis EC, Dinarello CA, Koreth J, Reddy P. α1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood . 2018 Mar 22;131(12):1372-1379.
  8. Jerkins JH, Hamadani M, Zook F, Epperla N, Shaw BE, Saber W, Rizzo JD, Pasquini M, Chhabra S, Drobyski WR, Hari PN, Shah NN. Alpha-1-antitrypsin for the treatment of steroid-refractory acute gastrointestinal graft-versus-host disease. Am J Hematol . 2017 Oct;92(10):E610-E611.
  9. Giannoni L, Morin F, Robin M, Peyneau M, Schlageter MH, Desmier D, Pagliuca S, Sutra Del Galy A, Sicre de Fontbrune F, Xhaard A, Dhedin N, Moins-Teisserenc H, Peffault de Latour R, Socié G, Michonneau D. Human-Derived α1-Antitrypsin is Still Efficacious in Heavily Pretreated Patients with Steroid-Resistant Gastrointestinal Graft-versus-Host Disease. Biol Blood Marrow Transplant . 2020 Sep;26(9):1620-1626.
  10. Gergoudis SC, DeFilipp Z, Özbek U, Sandhu KS, Etra AM, Choe HK, Kitko CL, Ayuk F, Aziz M, Baez J, Ben-David K, Bunworasate U, Gandhi I, Hexner EO, Hogan WJ, Holler E, Kasikis S, Kowalyk SM, Lin JY, Merli P, Morales G, Nakamura R, Reshef R, Rösler W, Srinagesh H, Young R, Chen YB, Ferrara JLM, Levine JE. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin.Blood Adv . 2020 Dec 22;4(24):6098-6105.
  11. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation . 1974;18:295–304.
  12. Ganetsky A , Frey NV , Hexner EO , Loren AW , Gill SI , Luger SM , Mangan JK , Martin ME , Babushok DV , Drobyski WR , Smith J , Timlin C , Freyer CW , Stadtmauer EA , Porter DL. Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. Bone Marrow Transplant . 2019 Feb;54(2):212-217 , Epub 2018 May 24.
  13. Roddy JV , Haverkos BM , McBride A , Leininger KM , Jaglowski S , Penza S , Klisovic R , Blum W, Vasu S , Hofmeister CC , Benson DM , Andritsos LA , Devine SM , Efebera YA. Tocilizumab for steroid refractory acute graft-versus-host disease.Leuk Lymphoma. 2016;57(1):81-5. Epub 2015 Jul 3.
  14. Haznedaroglu BZ, Haznedaroglu IC, Walker SL, et al. Ultrastructural and morphological analyses of the in vitro and in vivo hemostatic effects of Ankaferd Blood Stopper. Clin Appl Thromb Hemost2010;16(4):446–453.
  15. Zeiser R, Blazar BR. Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy. N Engl J Med . 2017 Nov 30;377(22):2167-2179.
  16. Weisdorf SA, Salati LM, Longsdor JA, Ramsay MKC, Sharp HL. Graft-versus-Host disease of the intestine: A protein-losing enteropathy characterized by fecal a1-antitrypsin.Gastroenterology 1983: 85: 1076–1081.
  17. Hagen LE, Schechter T, Luk Y, Brodovitch A, Gassas A, Doyle JJ. High alpha-1 antitrypsin clearance predicts severity of gut graft-versus-host disease (GVHD) in children. Pediatr Transplant . 2011 Sep;15(6):659-663.